MRKMerck Sharp & Dohme LLCSigning up patients
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 594 (planned)
- Started
- Apr 11, 2025
- Main results expected
- Dec 13, 2027
- Fully finished
- Dec 16, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Response Rate (CRR) at End of Treatment (EOT) per Lugano Response Criteria
Measured over: Up to approximately 31 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06890884 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC